TCM product approved for sale in Singapore
Lianhua Qingwen, a recommended medicine for treating patients with mild COVID-19 symptoms, has been approved as a Chinese proprietary medicine by the Health Sciences Authority in Singapore.
The designation means the product can be sold in the country as a medicine, the drug's manufacturer said on Wednesday.
Made by Shijiazhuang Yiling Pharmaceutical Co, in Shijiazhuang, Hebei province, the medicine meets Singapore's standards for registration as a Chinese patent medicine, it said.
The capsule, a traditional Chinese medicine used in the treatment of influenza, has been approved for sale as a medicine, food supplement or natural health product in a dozen countries and regions, including Brazil, Romania, Thailand and Ecuador. It can also be sold in the Hong Kong and Macao special administrative regions.
- China accelerates nuclear fusion engineering, targeting power generation demonstration by 2030
- Xinjiang leads China in cross-border rail traffic, central Asian connectivity in 2025
- Astronauts say training helped ensure safe return
- FAST reveals insights into cosmic signals
- Year's first private rocket mission takes off
- Taiwan separatists warned of action
